Telomir details Telomir-1 preclinical TNBC cell-killing data

Telomir Pharmaceuticals, Inc. reported new preclinical findings showing that its compound Telomir-1 selectively kills aggressive triple-negative breast cancer (TNBC) cells in laboratory studies.

Rhea-AI Filing Summary

Telomir Pharmaceuticals, Inc. reported new preclinical findings showing that its compound Telomir-1 selectively kills aggressive triple-negative breast cancer (TNBC) cells in laboratory studies. As Telomir-1 concentrations increased in human TNBC cell models, cancer cell survival dropped in a clear, concentration-dependent manner, and adding iron back restored cell growth, indicating the effect is tied to iron-dependent energy regulation.

The company explains that TNBC cells are highly metabolically active and rely heavily on iron, and that Telomir-1 appears to exploit this vulnerability while normal cells manage iron differently. Telomir-1 has also been shown previously to reset abnormal DNA methylation patterns, and the new data suggest its impact on TNBC may involve iron-dependent epigenetic enzymes linked to aggressive behavior and treatment resistance. Telomir plans to expand these studies to other cancer types and perform additional animal studies as it prepares an Investigational New Drug submission.

Insights

Oncology & Biotech Development Analyst

Preclinical data suggest Telomir-1 targets iron-dependent pathways in aggressive TNBC cells.

Telomir Pharmaceuticals describes laboratory results where Telomir-1 reduced survival of triple-negative breast cancer cells in a concentration-dependent way, with cell recovery when iron was reintroduced. This links the compound’s activity to iron-regulated cellular energy and mitochondrial function in a cancer subtype known for high metabolic demand and poor existing treatment options.

The company ties these findings to Telomir-1’s prior role in resetting abnormal DNA methylation and to iron-dependent histone demethylases such as KDM5A/B and KDM6B, which are associated with more aggressive, therapy-resistant phenotypes. This frames Telomir-1 as potentially acting through epigenetic control of iron use, oxidative stress, and energy metabolism, though evidence presented is limited to in vitro models.

Planned work includes extending studies to pancreatic and leukemia models and conducting further animal studies in preparation for an Investigational New Drug filing. Actual clinical relevance will depend on how these mechanistic and animal data translate into safety and efficacy once human trials are initiated.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Telomir Pharmaceuticals (TELO) report about Telomir-1 in triple-negative breast cancer?

The company reported that Telomir-1 significantly reduced survival of aggressive triple-negative breast cancer (TNBC) cells in laboratory studies, with a clear concentration-dependent loss of cancer cell growth and survival.

How does iron affect the activity of Telomir-1 in TNBC cells according to Telomir Pharmaceuticals (TELO)?

In the reported studies, adding iron back to Telomir-1–treated TNBC cells restored their survival, indicating that the compound’s activity is linked to iron-dependent regulation of cellular energy and mitochondrial function.

Why are the Telomir-1 findings important for aggressive triple-negative breast cancer, based on TELOs disclosure?

Telomir Pharmaceuticals notes that TNBC cells are among the most metabolically active breast cancers and depend heavily on iron, so Telomir-1’s disruption of iron-driven processes may target a core metabolic weakness that differs from normal cells’ iron handling.

What epigenetic mechanisms are mentioned in relation to Telomir-1 in the TELO 8-K?

The company states that Telomir-1 has previously reset abnormal DNA methylation patterns and that the new TNBC findings may involve iron-dependent histone demethylases such as KDM5A/B and KDM6B, which are thought to drive aggressive gene expression changes.

What future research plans for Telomir-1 did Telomir Pharmaceuticals (TELO) outline?

Telomir Pharmaceuticals plans to expand studies to additional cancer types, including pancreatic and leukemia models, and to conduct further animal studies in preparation for an Investigational New Drug (IND) submission.

Is Telomir-1 currently in clinical trials according to the TELO filing?

No. Telomir Pharmaceuticals describes itself as a preclinical-stage biotechnology company and indicates it will perform further animal studies in preparation for an IND submission, which is a step before human trials.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/08/2025 - 04:01 PM Learn about SEC filing dates

false 0001971532 0001971532 2025-10-08 2025-10-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 8, 2025

TELOMIR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

Florida		001-41952		87-2606031
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 SE 2nd St, Suite 2000, #1009

Miami, Florida, 33131

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (786) 396-6723

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, no par value		TELO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation.

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a preclinical-stage biotechnology company developing therapies that target epigenetic drivers of cancer, aging, and age-related disease, announced new findings demonstrating that Telomir-1 significantly reduces the survival of aggressive triple-negative breast cancer (TNBC) cells — a highly invasive form of breast cancer that lacks hormone and HER2 receptors, offers limited treatment options, and carries one of the poorest survival rates among breast cancer subtypes.

In laboratory studies using human triple-negative breast cancer cells, Telomir-1 produced a clear, concentration-dependent reduction in cancer cell survival. As Telomir-1 concentrations increased, more cancer cells lost their ability to grow and survive. When iron was added back to the system, the cells recovered, confirming that the compound’s activity is linked to the regulation of cellular iron and energy balance.

The iron dependency observed in this study is significant because aggressive cancer cells, such as those found in TNBC, are among the most metabolically active of all breast cancer types. These cells depend on iron to support their rapid growth and survival, and iron metabolism contributes directly to this aggressive behavior. By disrupting that iron-driven process, Telomir-1 appears to exploit a core metabolic weakness unique to these tumors. This selectivity is important because normal cells manage iron differently and are less dependent on it, suggesting that Telomir-1 may preferentially affect cancer cells while sparing healthy tissue.

Telomir-1 has previously been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in models of cancer and age-related disease. In TNBC, certain iron-dependent enzymes—known as Jumonji domain histone demethylases (KDMs), including KDM5A/B and KDM6B—are thought to drive gene expression changes that make cancer cells more aggressive and resistant to therapy. The new findings suggest that Telomir-1’s observed effects on energy regulation and iron balance may stem from its ability to influence these same epigenetic mechanisms. Many aggressive cancers show methylation changes that activate pathways controlling iron use, oxidative stress, and energy metabolism. By helping to restore normal epigenetic control, Telomir-1 may indirectly rebalance these pathways, offering new insight into its broader mechanism of action.

The Company plans to expand these studies to include additional cancer types, such as pancreatic and leukemia models, and to conduct further animal studies in preparation for its Investigational New Drug (IND) submission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELOMIR PHARMACEUTICALS, INC.
Dated: October 8, 2025	By:	/s/ Erez Aminov
	Name:	Erez Aminov
	Title:	Chief Executive Officer